Abemaciclib + Letrozole
Phase 2Active 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Endometrial Cancer
Conditions
Endometrial Cancer
Trial Timeline
Oct 10, 2020 → Dec 31, 2026
NCT ID
NCT04393285About Abemaciclib + Letrozole
Abemaciclib + Letrozole is a phase 2 stage product being developed by Eli Lilly for Endometrial Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04393285. Target conditions include Endometrial Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05872204 | Phase 2 | Recruiting |
| NCT04393285 | Phase 2 | Active |
Competing Products
20 competing products in Endometrial Cancer